Phase 3b, Multicenter, Randomized, Controlled, Double-blind Clinical Trial to Evaluate the Immunogenicity and Safety of Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Administration Alone in Adults Aged 18 to 59 Years.

 

Main Inclusion Criteria:

1. Not having had Dengue or Chikungunya;

2. Not having received vaccinations for dengue or Chikungunya;

3. The patient must not have been vaccinated within 14 days prior to inclusion with an inactivated vaccine or within 28 days prior to inclusion with a live attenuated vaccine;

4. You cannot have thrombocytopenia or a bleeding disorder;

5. You must not have used systemic corticosteroids for more than 14 days in the last 90 days.

 

Status: Will start soon.